Romano Danesi

Q: What Schools Are Affiliated With Romano Danesi

Romano Danesi is affiliated with the following schools: Consorzio ICoN, University of Milan, University of Florence, Sant'Anna School of Advanced Studies

Romano Danesi's AcademicInfluence.com Rankings

Romano Danesi

Computer Science

#7925

World Rank

#8341

Historical Rank

Machine Learning

#3101

World Rank

#3140

Historical Rank

Artificial Intelligence

#3403

World Rank

#3453

Historical Rank

Database

#4982

World Rank

#5176

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Romano Danesi's Degrees

Masters Artificial Intelligence University of Milan
Bachelors Computer Engineering University of Florence

Similar Degrees You Can Earn

Best Online Master's in Artificial Intelligence

Why Is Romano Danesi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Romano Danesi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. (2010) (439)
Molecular basis of resistance to azole antifungals. (2002) (420)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. (2006) (347)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial (2019) (227)
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. (2003) (222)
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients (2008) (209)
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. (2017) (208)
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs (2002) (201)
Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells (2005) (186)
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer (2008) (184)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer (2011) (178)
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors (2009) (170)
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. (2012) (162)
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells (2008) (157)
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (156)
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC (2018) (155)
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. (2002) (149)
The pharmacological bases of the antiangiogenic activity of paclitaxel (2013) (145)
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. (2019) (133)
Cardiac toxicity of antineoplastic anthracyclines. (2003) (125)
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. (2013) (123)
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. (2011) (117)
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 (2004) (114)
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. (2001) (108)
Clinical pharmacology of intravitreal anti-VEGF drugs (2018) (105)
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines (2004) (102)
Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). (1997) (101)
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. (1999) (100)
CYP2D6 polymorphisms and the impact on tamoxifen therapy. (2007) (99)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (2010) (99)
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. (2000) (97)
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib (2008) (95)
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. (1997) (95)
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects (2017) (95)
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells (2012) (92)
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer (2006) (92)
Polycomb genes and cancer: time for clinical application? (2012) (90)
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer (2011) (89)
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer (2011) (89)
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (88)
EPMA position paper in cancer: current overview and future perspectives (2015) (86)
Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. (1990) (86)
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. (2011) (85)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 (2004) (85)
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel (2008) (82)
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. (2011) (81)
Effect of suramin on human prostate cancer cells in vitro. (1991) (79)
Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. (1993) (78)
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA (2016) (78)
The emerging role of histone lysine demethylases in prostate cancer (2012) (78)
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells (2005) (74)
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. (2018) (73)
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer (2003) (72)
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. (1999) (71)
Hematologic toxicity of immunosuppressive treatment. (2004) (70)
Geranylgeraniol Overcomes the Block of Cell Proliferation by Lovastatin in C6 Glioma Cells (1998) (70)
A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity (2006) (69)
Cancer stem cell epigenetics and chemoresistance. (2009) (69)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients (2008) (68)
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections (2002) (67)
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation (2011) (65)
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma (2005) (65)
Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples (2008) (65)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (64)
Periodontal tissue disposition of azithromycin. (1997) (64)
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. (2015) (64)
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. (2001) (62)
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo (1999) (61)
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. (1995) (61)
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. (2002) (61)
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer (2008) (59)
Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. (2003) (59)
Pharmacogenetic determinants of anti-cancer drug activity and toxicity. (2001) (59)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (58)
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer (2006) (58)
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. (2007) (56)
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. (2011) (56)
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy (2019) (55)
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients (2019) (55)
5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer (2008) (55)
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. (2011) (54)
Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. (1991) (54)
Suramin, a novel antitumor compound (1990) (53)
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment (2018) (53)
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. (2009) (53)
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients (2010) (52)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper (2018) (52)
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer (2010) (52)
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study* (2001) (52)
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. (2004) (51)
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. (2017) (51)
Pharmacological Issues of Linezolid (2010) (51)
Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. (1986) (51)
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. (2014) (50)
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. (2016) (50)
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. (2012) (50)
A pilot study of suramin in the treatment of metastatic renal cell carcinoma (1991) (50)
Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. (1995) (49)
Histone lysine demethylases in breast cancer. (2013) (49)
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients (2006) (49)
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (48)
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients (2016) (48)
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. (2017) (48)
In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. (2001) (47)
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. (2002) (47)
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies☆ (2021) (47)
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. (2001) (47)
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview (2016) (46)
Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. (1996) (46)
The effects of the somatostatin analog octreotide on angiogenesis in vitro. (1996) (45)
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. (2009) (45)
Teratogenesis and immunosuppressive treatment. (2004) (45)
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines (2009) (45)
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. (1998) (45)
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study (2020) (45)
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer (2015) (44)
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. (2013) (44)
Radiomics and liquid biopsy in oncology: the holons of systems medicine (2018) (43)
Pharmacokinetic Optimisation of Treatment Schedules for Anthracyclines and Paclitaxel in Patients with Cancer (1999) (43)
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. (2017) (43)
Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. (1994) (43)
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide (2013) (43)
Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. (1995) (42)
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK‐Positive NSCLC With Disease Progression During Crizotinib Treatment (2017) (42)
Might adriamycinol contribute to adriamycin-induced cardiotoxicity? (1985) (41)
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients (2006) (41)
Genetic variation: effect on prostate cancer. (2014) (40)
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. (2001) (40)
Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat. (1991) (40)
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia (2014) (39)
Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid (2013) (39)
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. (2012) (38)
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. (2020) (38)
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma (2008) (37)
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. (2007) (35)
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. (2007) (35)
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. (2009) (35)
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile (2005) (35)
Pharmacogenetics of anti-estrogen treatment of breast cancer. (2012) (34)
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells (2000) (34)
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. (2011) (34)
Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role (2005) (34)
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (33)
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. (2011) (33)
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. (2013) (33)
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. (2016) (33)
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study (2012) (33)
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? (2016) (32)
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non‐Small Cell Lung Cancer: The Role of Cancer Stem Cells (2018) (32)
Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. (1996) (32)
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. (2019) (32)
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients (2014) (32)
A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma (2010) (32)
Suramin in combination with weekly epirubicin for patients with advanced hormone‐refractory prostate carcinoma (1999) (31)
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. (2000) (31)
MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. (1994) (31)
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. (2016) (31)
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response (2018) (31)
Increased susceptibility of ras‐transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion (1995) (30)
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan (2014) (30)
Pharmacogenomics in non-small-cell lung cancer chemotherapy. (2009) (30)
Real‐Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2V617F mutation in Philadelphia‐negative chronic myeloproliferative neoplasms (2015) (30)
In vitro antiangiogenic activity of selective somatostatin subtype‐1 receptor agonists (2007) (30)
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. (2004) (30)
The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. (2021) (29)
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. (2012) (29)
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia (2015) (29)
Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. (2013) (29)
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients (2017) (28)
Implications of KRAS mutations in acquired resistance to treatment in NSCLC (2015) (28)
METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER (2010) (28)
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. (2004) (28)
Pharmacogenetics of neoplastic diseases: new trends. (2004) (28)
Pharmacogenomics and cancer stem cells: a changing landscape? (2011) (27)
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. (2015) (27)
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide (2021) (27)
Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma (2000) (27)
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. (2012) (27)
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. (1996) (26)
Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling (2005) (26)
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (2017) (26)
Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. (2000) (26)
Correlation of CDA , ERCC 1 , and XPD Polymorphisms with Response and Survival in Gemcitabine / Cisplatin ^ Treated Advanced Non ^ Small Cell Lung Cancer Patients (2008) (26)
Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients (2002) (25)
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. (2017) (25)
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients (2016) (25)
Case Report of a Successful Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and MRSA/Vancomycin-Resistant Enterococcus faecium Cholecystitis by Daptomycin (2011) (25)
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate (2009) (25)
KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. (2020) (25)
The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review (2018) (25)
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. (2019) (25)
Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase. (1986) (24)
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. (2013) (24)
Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study (2010) (24)
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. (2010) (24)
Limited sampling model for the analysis of 5‐fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer (2002) (24)
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success (2019) (24)
Understanding EGFR heterogeneity in lung cancer (2020) (24)
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC (2020) (24)
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. (2006) (24)
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. (1996) (24)
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. (2011) (23)
Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. (2009) (23)
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? (2010) (23)
A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed (2004) (23)
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance (2021) (22)
Effects of Octreotide on Angiogenesis (1996) (22)
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. (2019) (22)
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer. (2013) (22)
Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? (2020) (22)
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2017) (22)
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. (1997) (22)
Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics (2011) (22)
Androgen receptor (AR) splice variant 7 and full‐length AR expression is associated with clinical outcome: a translational study in patients with castrate‐resistant prostate cancer (2019) (22)
Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells (2001) (21)
Refining sorafenib therapy: lessons from clinical practice. (2015) (21)
Metronomic Chemotherapy for Metastatic Prostate Cancer (2010) (21)
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma (2013) (21)
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines (2009) (21)
A Benefit-Risk Assessment of Basiliximab in Renal Transplantation (2004) (21)
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. (2011) (21)
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer (2010) (21)
Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery (1999) (20)
Determinants of bone specific metastasis in prostate cancer. (2017) (20)
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis (2021) (20)
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. (2011) (20)
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. (2015) (19)
Suramin in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Metastatic Colorectal Cancer Patients Resistant to 5-FU+LV-Based Chemotherapy (1998) (19)
Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells (2010) (19)
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. (2012) (19)
Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. (1997) (19)
Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. (2012) (19)
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. (2019) (19)
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (19)
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo (2014) (18)
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. (2013) (18)
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. (2020) (18)
Linezolid Cerebrospinal Fluid Concentration in Central Nervous System Infection (2007) (18)
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. (2021) (18)
3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. (1993) (18)
Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy (2011) (17)
Phase II Study of High‐Dose Epirubicin in Untreated Patients with Small‐Cell Lung Cancer (1990) (17)
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. (2000) (17)
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors (2015) (17)
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer (2020) (17)
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529 (2004) (17)
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients (2021) (17)
EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. (2018) (17)
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. (2014) (17)
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine‐based chemotherapy. A phase II Study (1995) (17)
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. (2010) (17)
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. (2014) (17)
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. (2016) (17)
The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients (2012) (16)
Idarubicin and Idarubicinol Effects on Breast Cancer Multicellular Spheroids (2005) (16)
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer (2014) (16)
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro (2018) (16)
Clinical study on the efficacy of clofoctol in the treatment of infectious respiratory diseases. (1985) (16)
Clinical and experimental evidence of inhibition of testosterone production by suramin. (1996) (16)
Differential affinities of AF-DX 116, atropine and pirenzepine for muscarinic receptors of guinea pig gastric fundus, atria and urinary bladder: might atropine distinguish among muscarinic receptor subtypes? (1990) (16)
Superoxide anion production by doxorubicin analogs in heart sarcosomes and by mitochondrial NADH dehydrogenase. (1990) (16)
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. (2020) (16)
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. (2017) (15)
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy (2021) (15)
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. (2006) (15)
Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. (1989) (15)
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (15)
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report (2002) (15)
Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours? (2020) (15)
Molecular targeted treatments for fungal infections: the role of drug combinations. (2003) (15)
Precision Medicine in Lymphoma by Innovative Instrumental Platforms (2019) (15)
Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells (2010) (14)
erbB in NSCLC as a molecular target: current evidences and future directions (2020) (14)
Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics? (2011) (14)
In vitro studies on gemcitabine combinations with other antiblastics. (2006) (14)
AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer (2016) (14)
Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor (1992) (14)
Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens (1999) (13)
Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. (1990) (13)
Suicide Gene Therapy With the Yeast Fusion Gene Cytosine Deaminase/Uracil Phosphoribosyltransferase Is Not Enough for Pancreatic Cancer (2007) (13)
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines (2012) (13)
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. (2000) (13)
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report (2019) (13)
Ceramide analogues in apoptosis: a new strategy for anticancer drug development. (2003) (12)
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment (2017) (12)
Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma (2003) (12)
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). (2001) (12)
Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine (1998) (12)
Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. (1988) (12)
A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance (2018) (11)
Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role (2002) (11)
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (11)
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia (2017) (11)
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. (2011) (11)
Penetration of clofoctol into human lung. (1987) (11)
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation (2006) (11)
Individualized dosing with axitinib: rationale and practical guidance. (2018) (11)
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia (2017) (11)
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation (2013) (11)
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients (2015) (11)
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (2014) (11)
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies (2022) (11)
Exogenous doxorubicinol induces cardiotoxic effects in rats. (1987) (11)
Time‐Dependent Pharmacokinetics of 5‐Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer (2012) (10)
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. (2021) (10)
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. (2022) (10)
Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas (2001) (10)
Different recommendations for daptomycin dosing over time in patients with severe infections. (2014) (10)
The penetration of roxithromycin into human skin. (1990) (10)
Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors (2011) (10)
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? (2016) (10)
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. (2010) (10)
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. (2009) (10)
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. (1995) (10)
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence (2019) (10)
A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. (2020) (10)
Correlation of cytidine deaminase (CDA), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing 1 (ERCC1) genes single nucleotide polymorphisms (SNPS) with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer (NSCLC) patients (2007) (9)
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel (2021) (9)
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. (2021) (9)
Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats (2004) (9)
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study. (2001) (9)
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. (1991) (9)
Promoting predictive, preventive and personalised medicine: European event of global importance (2011) (9)
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer (2021) (9)
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (8)
Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule (2017) (8)
Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines. (1992) (8)
Ultrastructural and biochemical evidence of apoptosis induced by a novel inhibitor of protein geranylgeranylation in human MIA PaCa-2 pancreatic cancer cells. (1998) (8)
Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. (2016) (8)
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. (2009) (8)
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. (2017) (8)
Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4′-amino-3′-hydroxy-doxorubicin (2004) (8)
Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation. (1993) (8)
Effects of 4'-O-tetrahydropyranyl-doxorubicin on isolated perfused rat heart and cardiac mitochondrial cytochrome C oxidase activity. (1987) (8)
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms? (2008) (8)
Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach (2011) (8)
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. (2018) (8)
Administration Interval and Daptomycin Toxicity: A Case Report of Rhabdomyolysis (2010) (8)
Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart. (1992) (7)
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone (2020) (7)
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. (1994) (7)
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2018) (7)
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients (2016) (7)
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. (2009) (7)
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study (2003) (7)
Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015 (2016) (7)
Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report. (2008) (7)
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients (2022) (7)
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer (2020) (7)
Should CYP2D6 be genotyped when treating with tamoxifen? (2017) (7)
EPMA-World Congress 2015 (2016) (7)
Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. (2015) (7)
Trapidil inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea. (1995) (7)
Should CYP2D6 be genotyped when treating with tamoxifen? (2016) (7)
General and cardiac toxicity of adriamycinol in rats. (1986) (7)
5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer (2001) (7)
Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. (2017) (7)
A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. (1988) (6)
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. (2019) (6)
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. (2020) (6)
Efficacy and safety of basiliximab in kidney transplantation (2005) (6)
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment (2017) (6)
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy (2019) (6)
The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer (2007) (6)
Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (6)
The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells. (2002) (6)
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. (2019) (6)
Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. (1994) (6)
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. (2016) (6)
The pharmacokinetic profile of clofoctol in rat plasma and tissues after oral and rectal administration. (1986) (6)
Evaluation of the JT and corrected JT intervals as a new ECG method for monitoring doxorubicin cardiotoxicity in the dog. (1989) (5)
Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. (2003) (5)
Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time (2019) (5)
Genetic interaction of P 2 X 7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (5)
Ceramide Analogues in Apoptosis: A New Strategy for Anticancer Drug Development (2003) (5)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. (2004) (5)
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) mul (2021) (5)
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors. (2004) (5)
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. (2020) (5)
Imatinib administration in two patients with liver metastases from GIST and severe jaundice (2003) (5)
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. (2003) (5)
Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)‐Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition (2006) (5)
The influence of amrinone on cardiac toxicity induced by adriamycin in rats. (1986) (4)
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. (2022) (4)
Clinical pharmacology differences among proteasome inhibitors: implications for their use in clinical practice. (2021) (4)
Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer (2021) (4)
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. (2018) (4)
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. (2005) (4)
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. (2022) (4)
[A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. (1989) (4)
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. (2021) (4)
Suramin as an anticomplementary agent in xenotransplantation. (1992) (4)
The effect of rhGM‐CSF on the proliferation of osteogenic sarcoma cells (1991) (4)
A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study (2021) (4)
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data (2022) (4)
Human skin disposition of cefpodoxime after oral administration of its proxetil ester. (1992) (4)
Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. (1994) (4)
DPYD and UGT 1 A 1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2018) (4)
An EZH 2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients (2012) (4)
Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC: 2PD (2016) (3)
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. (2019) (3)
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs (2022) (3)
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? (2017) (3)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (3)
Pharmacokinetics of irinotecan: Comparison of intravenous and intra-arterial administration in patients with liver metastases (2008) (3)
TOP2A mRNA expression in HER2 negative breast cancer. (2009) (3)
Depression of the immune responsiveness in mice treated with thioacetamide after antigen exposure. (1989) (3)
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (3)
Chemoembolization is effective as second-line therapy in patients with colorectal carcinoma metastatic to the liver. (2002) (3)
Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. (2006) (3)
Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study (2021) (3)
Suramin therapy for malignant thymoma: a case report. (1994) (3)
The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs (2014) (3)
Steroids in prostate cancer: the jury is still out... and even more confused. (2015) (3)
Genotype A1/A2 associated with neuroleptic malignant syndrome. (2005) (3)
The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1). (1992) (3)
Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
Morphohistochemical characterization of suramin--induced chronic toxicity in rat kidney. (1992) (3)
Biologic basis of ovarian metastasis of colorectal cancer. (2004) (3)
Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation (2021) (2)
Nicotine Metabolite Ratio in Smokers: A Real World Experience (2017) (2)
The low opioid consumption in Italy depends on late palliative care (2013) (2)
Fructose-1,6-diphosphate reduces acute ECG changes due to doxorubicin in isolated rat heart (1988) (2)
Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA (2019) (2)
Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs (2015) (2)
Doxorubicin affects both the number and the morphology of specific atrial granules in dog heart. (1988) (2)
Mitoxantrone, prednisone, pentostatin and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL) (2003) (2)
Intravenous versus intrahepatic arterial 5-fluorouracil/leucovorin for treatment of colorectal cancer metastases. (2002) (2)
Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue: (2009) (2)
Doxorubicin cardiotoxicity is reduced by pretreament with the iron chelator ADR-529 (1990) (2)
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3- deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells (2012) (2)
Changes of specific atrial granules induced by doxorubicin in dog's heart. (1990) (2)
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (2)
ResearchHypertension and hand-foot skin reactions related to VEGFR 2 genotype and improved clinical outcome following bevacizumab and sorafenib (2015) (2)
Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. (2022) (2)
Molecular mechanisms involved in the synergistic interaction of the EZH 2 inhibitor 3-deazaneplanocin A ( DZNeP ) with gemcitabine in pancreatic cancer cells (2012) (2)
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. (2022) (2)
Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. (2021) (2)
EPMA position paper in cancer: current overview and future perspectives (2015) (1)
Predicting survival with artificial neural networks. (2003) (1)
A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
Comment on “High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma” (2015) (1)
Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity (2010) (1)
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (2011) (1)
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. (2017) (1)
Impact of locoregional approaches to liver metastases in patients with colorectal cancer. (2003) (1)
Inhibitory Effect of Suramin and Heparin-Like Drugs on Experimental Angiogenesis (1993) (1)
Pharmacogenetics in oncology (2008) (1)
A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. (2003) (1)
[The physiopathological aspects of the atrial natriuretic factor]. (1992) (1)
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World (2018) (1)
Pharmacogenetics and Personalized Medicine (2017) (1)
Chronic administration of suramin induces neurotoxicity in rats (1997) (1)
Cancer Therapy : Clinical Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide , Celecoxib , and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (1)
A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed (2001) (1)
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents. (2005) (1)
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies (2021) (1)
[Recent pharmacotoxicologic and clinical findings on adriamycin]. (1985) (1)
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. (2013) (1)
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. (2021) (1)
Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf—Letter (2012) (1)
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC (2014) (1)
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. (2022) (1)
The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview (2016) (1)
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. (2012) (1)
1616PLIQUID BIOPSY TO MONITOR THE EVOLUTION OF NSCLC EGFR+DURING TREATMENT WITH GEFINTINIB. (2014) (1)
the Modulation of Gemcitabine Activity Outcome and Pharmacologic Aspects Underlying Its Role in MicroRNA-21 in Pancreatic Cancer : Correlation with Clinical (2010) (1)
Cardiac toxicity and antitumor activity of 4′-deoxy-4′-iodo-doxorubicinol (2008) (1)
Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. (2017) (1)
Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer. (2017) (1)
Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (1)
Molecular mechanisms underlying the synergistic interaction of erlotinib , an epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor , with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells (2008) (1)
[Preclinical pharmacology and clinical uses of topotecan]. (1999) (0)
SP147 Pharmacogenomics in pancreatic cancer (2009) (0)
Inhibition of acetylcholinesterase in patients receiving irinotecan (CPT-11) (2004) (0)
Sequence E ffect o f I rinotecan a nd F luorouracil T reatment on P harmacokinetics a nd T oxicity i n C hemotherapy-Nai ve Metastatic C olorectal C ancer P atients (2001) (0)
Epigenetics and breast cancer – prediction of drug activity (2008) (0)
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients (2010) (0)
Circulating biomarkers of response to immunotherapy in cancer treatment. (2019) (0)
Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens (2013) (0)
MC13-0067 Association between Kras mutation in circulating cell-free tumor DNA and clinical progression of colorectal cancer in patients receiving cetuximab (2013) (0)
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. (2013) (0)
[Clinical efficacy of clofoctol in treating odontogenic infections]. (1986) (0)
Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients. (2014) (0)
A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC). (2020) (0)
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] (2021) (0)
EGFR/KRAS-Germline mutation analyses in advanced non-small cell lung cancer (NSCLC) patients treated with Gefitinib/Erlotinib (2008) (0)
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia (2015) (0)
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. (2012) (0)
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (0)
Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples (2021) (0)
Polycomb gene expression and single-nucleotide-polymorphisms (SNPS) in triple negative breast cancer (TNBC) patients. (2012) (0)
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients (2006) (0)
Dihydropyrimidine dehydrogenase (DPD) deficiency: how to translate it in clinical practice? (2017) (0)
Pleiotropic drug resistance in epithelial ovarian cancer (1991) (0)
Genetic determinants in the study of colorectal cancer. (2004) (0)
Cx. Incorporation of ctDNA analysis into routine follow-up for early detection of relapse may allow earlier initiation of alternate treatment modalities. Legal entity responsible for the study: The National Committee on Health Research (2019) (0)
Suramin in metastatic colorectal cancer patients pretreated with fluoropyrimidine-based chemotherapy: a phase II trial (1995) (0)
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA. (2016) (0)
Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. (2019) (0)
Effect of suramin on ethanol-induced gastric mucosal injury: Relationship between tissue distribution and severity of damage (1996) (0)
Preclinical Development Molecular Mechanisms Involved in the Synergistic Interaction of the EZH 2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells (2012) (0)
Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (0)
610 POSTER Synergistic cytotoxicity, inhibition of Akt and c-Kit phosphorylation and modulation of gene expression by sorafenib and gemcitabine in human pancreatic cancer cells (2006) (0)
EPMA-World Congress 2015 (2016) (0)
Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration (2007) (0)
The emerging role of histone lysine demethylases in prostate cancer (2012) (0)
Precision Medicine in Oncology: Glossary of Relevant Scientific Terms (2021) (0)
2162 : Synergistic Antitumor Activity of Zd6474, an Inhibitor of VEGFR and EGFR Signaling, With Gemcitabine and Ionizing Radiation Against Pancreatic Cancer (2006) (0)
Lessons from the first ecancer symposium on angiogenesis in gastric cancer (2015) (0)
The pharmacological bases of the antiangiogenic activity of paclitaxel (2013) (0)
Pharmacogenetics of Angiogenesis (2010) (0)
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Fast (2008) (0)
Chapter 7 Molecular mechanisms involved in the synergistic interaction of the EZH 2 inhibitor 3-deazaneplanocin A ( DZNeP ) with gemcitabine in pancreatic cancer cells (2013) (0)
Abstract C100: KRAS mutations in circulating cell-free DNA of colorectal cancer patients in progression after MoAb anti-EGFR therapy. (2013) (0)
Antiproliferative effects and apoptosis induced by novel selective inhibitors of geranylgeranylation of cellular proteins (1997) (0)
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)
Targeting the upregulated PI3K-PDK1-Akt pathway: a drug discovery approach of treating cancer. (2012) (0)
Phenylacetate inhibits protein prenylation in LNCaP cells transfected with the T24 H-ras gene (1995) (0)
Capecitabine/Irinotecan Is Active and Well Tolerated in Patients with Advanced Colorectal Cancer (2001) (0)
Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol (2021) (0)
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel (2021) (0)
EZH2 Expression in Colorectal (CRC) Cancer: Single Nucleotide Polymorphism (SNP) Characterization and Correlation With Clinico-Pathological and Molecular Parameters (2012) (0)
Comparison of ddPCR and sdPCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. (2023) (0)
C01*The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients (2016) (0)
Low-toxic combination chemotherapy for limited small-cell lung cancer (1989) (0)
Preparation and antiproliferative activity of phosphorus- and sulfur-containing geranylgeranyl derivatives (1997) (0)
C11 Cytotoxic drugs (2011) (0)
Irinotecan in 5-fluorouracil-refractory colorectal cancer. (2002) (0)
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs (2022) (0)
Nanoscale engagement of immune checkpoint inhibitor PD-L1 in membrane lipid rafts (2022) (0)
Determination of mitotane and principal metabolite by a simple HPLC-UV method and its validation in human plasma sample (2019) (0)
H17Detection of secondary mutations associated with drug resistance in circulating tumor dna of patients with advanced ALK+ NSCLC (2015) (0)
Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC. (2019) (0)
Reply (2004) (0)
Population pharmacokinetics and probability of target attainment of meropenem 1 in critically ill patients 2 3 (2019) (0)
Embryonic stem cell pathways and chemotherapy response: an unexplored route. (2013) (0)
[Effect of amrinone on the cardiotoxicity induced by adriamycin in the rat]. (1985) (0)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (0)
Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer. (2018) (0)
PHARMACOGENETIC EVALUATION OF AURORA A KINASE IN COLORECTAL CANCERS (2007) (0)
E07DPYD c.1905 + 1G > A and c.2846A > T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer (2015) (0)
1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients (2020) (0)
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region (2020) (0)
Prevention of Capecitabine Toxicity Using a 5-FU Test Dose (2018) (0)
PLASMA/SALIVA AND GENOTYPIC/PHENOTYPIC DIFFERENCES OF NICOTINE METABOLITE RATIO. (2018) (0)
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. (2022) (0)
A polymorphism in a transporter of testosterone as a determinant of androgen independence in prostate cancer (2008) (0)
Deposited in DRO : 12 June 2012 Version of attached le : Published Version Peer-review status of attached le : Peer-reviewed Citation for published item : (2014) (0)
Synergistic chemotherapeutic activity of gemcitabine and fluvastatin on pancreas cancer in vitro (2001) (0)
Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. (2011) (0)
LASER MICRODISSECTION (LMD) AND PRIMARY CELL CULTURES IMPROVE PHARMACOGENETIC ANALYSIS IN PANCREATIC ADENOCARCINOMA ALLOWING THE USE OF GENE EXPRESSION LEVELS AND WHO GRADING AS PROGNOSTIC MARKERS (2008) (0)
May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients? (2019) (0)
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2017) (0)
Evaluation of EZH2 SNPs in cholangiocarcinoma patients. (2012) (0)
V79/AP4 cell growth is suppressed by drugs which inhibit bfGf-mitogenic activity and by antisense oligonucleotides to bFGF (1992) (0)
Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. (2013) (0)
Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC. (2018) (0)
Characteristics of smokers according to their Nicotine Metabolite Ratio, preliminary results from a real-life experience (2017) (0)
A novel multi-target pyrazolopyrimidine derivative with anti-neoplastic properties, CLM29, is active against medullary thyroid cancer in vitro and in vivo (2013) (0)
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report (2007) (0)
OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients (2016) (0)
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed in bladder transitional cell cancer (2006) (0)
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology (2019) (0)
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. (2012) (0)
Ceramide Analogues as a New Strategy for Anticancer Drug Development (2000) (0)
New geranylgeranylderivate, process for their preparation and related pharmaceutical compositions (1996) (0)
Resistance to biologic drugs (2014) (0)
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
Simultaneous, but not consecutive combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro (2017) (0)
PP069 Health Technology Assessment Of Radium-223 Dichloride In Resistant Metastatic Prostate Cancer (2017) (0)
MYCOPHENOLATE MOPHETIL AND PANCREAS TRANSPLANT ALO (2005) (0)
AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS. (2012) (0)
[Possible role of adriamycinol in the cardiotoxicity induced by adriamycin in the rat]. (1985) (0)
Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine (2006) (0)
Case Study of the Month Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP 1 B 1 Isoforms : Suggestion for Changing Paradigms ? (2008) (0)
The Role of Adjuvant Therapy After Liver Resection for Colorectal Metastases. (2001) (0)
Abstract P1-08-31: Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy (2013) (0)
Doxorubicin dose-dependently widens the SαT segment of the ECG the isolated rat heart segment of the ECG in th isolated rat heart (1989) (0)
TISSUE PENETRATIONS AND EFFICACY OF CEFPODOXIME PROXETIL IN THE TREATMENT OF ODONTOGENIC INFECTIONS (1993) (0)
Rebuttal letter: Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes. (2019) (0)
Lung tissue penetration and plasma pharmacokinetics of azithromycin after multiple oral doses of 500 and 1000 mg in adults (2001) (0)
EZH 2 polymorphism and benefit from bevacizumab in colorectal cancer : another piece to the puzzle (2012) (0)
The heparan sulfate HHS-5 inhibits corneal angiogenesis induced by chemical cauterization in rats ☆ (1992) (0)
Pharmacogenetics of Antiangiogenic Therapy (2008) (0)
CYTOTOXIC ACTIVITY OF INHIBITORS OF ARACHIDONIC ACID METABOLISM IN HUMAN PANCREATIC CANCER CELLS IN VITRO (2000) (0)
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients (2015) (0)
The rs 2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-RelatedMacular Degeneration Patients (2014) (0)
3067 POSTER Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation (2007) (0)
Genes involved in gemcitabine activity: pancreas cancer vs primary cell cultures (2006) (0)
Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab (2012) (0)
Embryonic stem cell pathways and chemotherapy response: an unexplored route. (2013) (0)
MICRORNA-21 FROM BENCH TO BEDSIDE AND BACK: A POTENTIAL MARKER OF CLINICAL OUTCOME AND A TARGET TO OVERCOME RESISTANCE TO GEMCITABINE IN PANCREATIC CANCER (2010) (0)
Abstract 4375: Sunitinib alone and in combination with SN-38 is active against anaplastic thyroid cancer (2012) (0)
AbstractAzidothymidine (AZT), 5-fluorouracil (5-FU) and l-folinic acid (FA): A pilot study in metastatic colorectal cancer (MCRC) (1994) (0)
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response (2018) (0)
Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer. (2018) (0)
Effects of suramin on V79-AP4 fibroblast cell line (1990) (0)
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. (2023) (0)
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment (2017) (0)
242: Pharmacogenetics Determinants of Anticancer Activity of Intravescical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder (2007) (0)
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA (2015) (0)
Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. (2018) (0)
THE OFFICIAL JOURNAL OF SOCIETÀ ITALIANA DI FARMACOLOGIA (2022) (0)
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years (2023) (0)
12 Pharmacogenetics of drug transporters (2010) (0)
Doxorubicin cardiotoxicity in the dog: A morphofunctional study (1988) (0)
Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers. (1988) (0)
Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients (2019) (0)
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
EP-0997: Polymorphisms of Akt and EZH2 as predict factor of radiochemotherapy in patients with glioblastoma (GBM) (2013) (0)
ICRF-187 prevents ECG alterations induced by doxorubicin treatment in the rat (1990) (0)
Exploratory analysis of circulating pro- and antiangiogenic factors in metastatic colorectal cancer (mCRC) patients, treated with GONO-FOLFOXIRI plus bevacizumab (BV). (2010) (0)
Pharmacogenetics to predict adverse drug reactions in oncology: distant goal or reality? (2015) (0)
Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28]. (2019) (0)
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (0)
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (0)
Single nucleotide polymorphisms and clinical outcome in biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine (2008) (0)
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report (2019) (0)
PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience (2016) (0)
Doxorubicin modifies plasma levels of immunoreactive atrial natriuretic factor (1990) (0)
Genome Wide Association Studies (GWAS) (2018) (0)
Radiosensitizing potential of small organic molecules toward hypoxic tumor cells in the radiotherapy (2008) (0)
Expression of gemcitabine and cisplatin-related genes according to histology and stage in non-small-cell lung cancer (NSCLC) (2008) (0)
Stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side-chain as inhibitors of prenyl protein transferases (2005) (0)
Author's reply: To PMID 22443211. (2013) (0)
PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy (2017) (0)
Small Cell Lung Cancer Patients − Advanced Non Treated − Response and Survival in Gemcitabine / Cisplatin Polymorphisms with XPD , and CDA , ERCC 1 Correlation of (2008) (0)
Taxol inhibits protein isoprenylation in PC-3 prostate cancer cells (1995) (0)
Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue (2009) (0)
Pathophysiology and pharmacological targets of diabetic macular edema : an 1 updated review (2014) (0)
In vitro schedule-dependent interaction and gene expression modulation by gemcitabine and pemetrexed in non-small cell lung cancer (NSCLC) cell lines. (2004) (0)
228PPATTERN OF DIHYDROPYRIMIDINE DEHYDROGENASE GENETIC VARIANTS IN PATIENTS WITH VARIOUS DEGREES OF TOLERABILITY OF FLUOROPYRIMIDINE TREATMENT. (2014) (0)
Cytotoxic Drugs (2019) (0)
Control of cell growth by ceramide analogues: a new strategy for anticancer drug development (1999) (0)
Immune Checkpoint Inhibitors and Cardiotoxicity: Reverse Translational Research by Using Real World Safety Data from the European Spontaneous Reporting System (2021) (0)
A NEW HPLC-UV METHOD COMPARED WITH HPLC-MS FOR DAPTOMYCIN LEVELS IN HUMAN PLASMA SAMPLES (2020) (0)
Advances in Brief MCF-10 A Cells Infected with the int-20 ncogene Induce Angiogenesis in the Chick Chorioallantoic Membrane and in the Rat Mesentery 1 (2007) (0)
SAFETY MATTERS: THE TROUBLED AND FINALLY SUCCESSFUL STORY OF DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETIC TEST IN CANCER PATIENTS (2021) (0)
D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients (2007) (0)
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens. (2005) (0)
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients (2023) (0)
Effect of fluvastatin on colon tumor cells (1996) (0)
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib (2022) (0)
Breast lymphomas around breast implants. (2014) (0)
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Romano Danesi?

Romano Danesi is affiliated with the following schools:

Romano Danesi's Academic­Influence.com Rankings

Romano Danesi's Degrees

Similar Degrees You Can Earn

Why Is Romano Danesi Influential?

Romano Danesi's Published Works

Published Works

What Schools Are Affiliated With Romano Danesi?

Romano Danesi's AcademicInfluence.com Rankings